5RA-5RCM is developed by Buddhist Tzu Chi General Hospital.

What development phase is 5RA-5RCM in?

5RA-5RCM is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

5RA-5RCM

Buddhist Tzu Chi General Hospital · FDA-approved active Small molecule Quality 6/100

5RA-5RCM, marketed by Buddhist Tzu Chi General Hospital, is a drug with an unknown mechanism of action and a key composition patent expiring in 2028. The primary strength of 5RA-5RCM lies in its current market presence, despite the lack of detailed clinical trial results and revenue data. The primary risk is the uncertainty surrounding its mechanism of action, which may impact future regulatory and market acceptance.

At a glance

Generic name	5RA-5RCM
Also known as	Pariet x 10 days, Hiconcil x 1st 5 days then, Klaricid x last 5 days +, Flagyl x last 5 days
Sponsor	Buddhist Tzu Chi General Hospital
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Comparison Between Ten Days Sequential Treatment and Traditional Three Combined Treatment of Helicobacter Pylori (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

5RA-5RCM CI brief — competitive landscape report
5RA-5RCM updates RSS · CI watch RSS
Buddhist Tzu Chi General Hospital portfolio CI